# MoonLake Immunotherapeutics: overview

MLTX · Nasdaq · CIK 1821586 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mltx.md) · [Financials](/companies/mltx/financials.md) · [Filings](/companies/mltx/filings.md) · [Insiders](/companies/mltx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.56)](/filings/0001821586-25-000022.md) | not reported | [(0.63)](/filings/0001821586-26-000007.md) | [(0.87)](/filings/0001821586-26-000010.md) | [(1.10)](/filings/0001821586-25-000022.md) | not reported | [(0.98)](/filings/0001821586-26-000007.md) | [(0.84)](/filings/0001821586-26-000010.md) |
| Free cash flow | $m | [(25.4) d](/filings/0001821586-25-000022.md) | [(48.6) d](/filings/0001821586-26-000002.md) | [(38.2)](/filings/0001821586-26-000007.md) | [(54.5) d](/filings/0001821586-26-000010.md) | [(44.5) d](/filings/0001821586-25-000022.md) | [(58.8) d](/filings/0001821586-26-000002.md) | [(66.3)](/filings/0001821586-26-000007.md) | [(55.6) d](/filings/0001821586-26-000010.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.31)](/filings/0001213900-22-008253.md) | [(1.70)](/filings/0001821586-25-000006.md) | [(0.73)](/filings/0001821586-26-000002.md) | [(1.89)](/filings/0001821586-26-000002.md) | [(3.53)](/filings/0001821586-26-000002.md) |
| Free cash flow | $m | not reported | [(55.9)](/filings/0001821586-25-000006.md) | [(43.1)](/filings/0001821586-26-000002.md) | [(117)](/filings/0001821586-26-000002.md) | [(196)](/filings/0001821586-26-000002.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mltx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $311.5m | 16,001,284 |  | Unchanged |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $136.3m | 6,999,025 |  | Added +590,162 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $65.5m | 3,365,507 |  | Added +974,846 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $64.3m | 3,451,628 |  | Not compared |
| [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $62.4m | 3,205,433 |  | Reduced −1,275,000 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $60.1m | 3,085,906 |  | Not compared |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $52.1m | 2,675,000 |  | Added +1,175,000 |
| [Weiss Asset Management LP](/funds/1357550.md) | 2026-06-30 | $50.3m | 2,581,813 |  | Added +873,485 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $38.4m | 1,972,893 |  | Added +649,165 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $33.4m | 1,715,349 |  | Added +593,037 |

## Recent filings

[All 329 filings](/companies/mltx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-30 | 16:15 ET | [8-K](/filings/0001213900-26-105240.md) | 8.01 Other events | 0001213900-26-105240 |
| 2026-08-10 | 07:46 ET | [10-Q](/filings/0001821586-26-000010.md) | Quarterly report, period 2026-06-30 | 0001821586-26-000010 |
| 2026-08-10 | 07:15 ET | [8-K](/filings/0001213900-26-086939.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-086939 |
| 2026-07-15 | 17:31 ET | [8-K](/filings/0001213900-26-078031.md) | 8.01 Other events | 0001213900-26-078031 |
| 2026-06-29 | 17:20 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001697.md) | Ownership report, active investor, amended | 0000921895-26-001697 |
| 2026-06-25 | 06:18 ET | [8-K](/filings/0001213900-26-071721.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-071721 |
| 2026-06-22 | 07:00 ET | [8-K](/filings/0001213900-26-070362.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-070362 |
| 2026-06-09 | 16:30 ET | [8-K](/filings/0001213900-26-066821.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-066821 |
| 2026-06-01 | 06:20 ET | [8-K](/filings/0001213900-26-063125.md) | 1.01 Entry into a material agreement | 0001213900-26-063125 |
| 2026-05-11 | 08:55 ET | [10-Q](/filings/0001821586-26-000007.md) | Quarterly report, period 2026-03-31 | 0001821586-26-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001821586-26-000002.md), filed Feb 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1821586
- Tickers: MLTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.